1 insider has bought $493k of Ascendis Pharma A/S shares across 2 disclosed dealings since August 2026. 2 of those have been scored against our six-point signal check.
| Aug 14, 2026 | BIENAIME JEAN JACQUES — director | $222,219 |
| Aug 14, 2026 | BIENAIME JEAN JACQUES — director | $270,435 |
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Every row is a public regulatory disclosure — a Form 4 filing with the SEC — collected within minutes of being published. We don’t take company submissions and we don’t edit the numbers; the only thing we add is the rating and the reasoning behind it.
Sometimes. A insider buying with their own money is one of the few honest signals in the market, but plenty of purchases are routine — small top-ups, scheme allocations, or a well-paid executive rounding out a holding. That’s what our six-point check is for: it separates the conviction buys from the housekeeping, and shows you which is which.
The pipeline runs every 15 minutes through the trading day, so a new disclosure appears here shortly after it’s filed. Company stats refresh daily.
Yes — that’s what the app is for. Follow Ascendis Pharma A/S and you’ll get a push the moment a insider files, with the full analysis attached, plus alerts if the price moves after a buy you’re following.
No. ddbx rates the conviction behind insider buys and shows the reasoning. It’s information, never a recommendation, and never a guarantee. What you do with it is your call.